Zealand Pharma A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0060257814
DKK
505.80
12.3 (2.49%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

246.85 k

Shareholding (Jun 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 34,797 Million ()

stock-summary
P/E

5.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.86

stock-summary
Return on Equity

43.80%

stock-summary
Price to Book

2.29

Revenue and Profits:
Net Sales:
9,088 Million
(Quarterly Results - Jun 2025)
Net Profit:
7,574 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.56%
0%
13.56%
6 Months
8.54%
0%
8.54%
1 Year
-32.24%
0%
-32.24%
2 Years
48.59%
0%
48.59%
3 Years
141.32%
0%
141.32%
4 Years
276.34%
0%
276.34%
5 Years
121.65%
0%
121.65%

Zealand Pharma A/S for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
97.92%
EBIT Growth (5y)
66.52%
EBIT to Interest (avg)
-66.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
2.25
EV to EBIT
2.55
EV to EBITDA
2.54
EV to Capital Employed
-28.59
EV to Sales
2.06
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
43.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 26,551.91% vs 227.88% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 2,686.65% vs 8.36% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9,088.30",
          "val2": "34.10",
          "chgp": "26,551.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8,519.50",
          "val2": "-260.90",
          "chgp": "3,365.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.10",
          "val2": "14.40",
          "chgp": "-36.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-168.40",
          "val2": "-37.20",
          "chgp": "-352.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7,573.70",
          "val2": "-292.80",
          "chgp": "2,686.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "936.70%",
          "val2": "-7,842.70%",
          "chgp": "877.94%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -81.71% vs 229.62% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -53.30% vs 27.12% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "62.70",
          "val2": "342.80",
          "chgp": "-81.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1,243.20",
          "val2": "-532.90",
          "chgp": "-133.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "40.90",
          "val2": "29.00",
          "chgp": "41.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "38.60",
          "val2": "-155.80",
          "chgp": "124.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,078.80",
          "val2": "-703.70",
          "chgp": "-53.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-20,243.30%",
          "val2": "-1,637.30%",
          "chgp": "-1,860.60%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
9,088.30
34.10
26,551.91%
Operating Profit (PBDIT) excl Other Income
8,519.50
-260.90
3,365.43%
Interest
9.10
14.40
-36.81%
Exceptional Items
-168.40
-37.20
-352.69%
Consolidate Net Profit
7,573.70
-292.80
2,686.65%
Operating Profit Margin (Excl OI)
936.70%
-7,842.70%
877.94%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 26,551.91% vs 227.88% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 2,686.65% vs 8.36% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
62.70
342.80
-81.71%
Operating Profit (PBDIT) excl Other Income
-1,243.20
-532.90
-133.29%
Interest
40.90
29.00
41.03%
Exceptional Items
38.60
-155.80
124.78%
Consolidate Net Profit
-1,078.80
-703.70
-53.30%
Operating Profit Margin (Excl OI)
-20,243.30%
-1,637.30%
-1,860.60%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -81.71% vs 229.62% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -53.30% vs 27.12% in Dec 2023

stock-summaryCompany CV
About Zealand Pharma A/S stock-summary
stock-summary
Zealand Pharma A/S
Pharmaceuticals & Biotechnology
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.
Company Coordinates stock-summary
Company Details
Sydmarken 11 , SOEBORG None : 2860
Registrar Details